174 related articles for article (PubMed ID: 30928962)
1. Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational study.
Yang M; Pan H; Lu L; He X; Chen H; Tao B; Liu W; Yi H; Tang S
BMJ Open; 2019 Mar; 9(3):e027321. PubMed ID: 30928962
[TBL] [Abstract][Full Text] [Related]
2. Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).
Xia YY; Hu DY; Liu FY; Wang XM; Yuan YL; Tu DH; Chen YX; Zhou L; Zhu LZ; Gao WW; Wang HY; Chen da F; Yang L; He PP; Li XT; He YJ; Sun F; Zhan SY
BMC Public Health; 2010 May; 10():267. PubMed ID: 20492672
[TBL] [Abstract][Full Text] [Related]
3. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study.
Lv X; Tang S; Xia Y; Wang X; Yuan Y; Hu D; Liu F; Wu S; Zhang Y; Yang Z; Tu D; Chen Y; Deng P; Ma Y; Chen R; Zhan S
PLoS One; 2013; 8(6):e65037. PubMed ID: 23750225
[TBL] [Abstract][Full Text] [Related]
4. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug reactions of anti-tuberculosis treatment among children with tuberculosis.
Laghari M; Talpur BA; Syed Sulaiman SA; Khan AH; Bhatti Z
Int J Mycobacteriol; 2020; 9(3):281-288. PubMed ID: 32862161
[TBL] [Abstract][Full Text] [Related]
6. Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors.
Javadi MR; Shalviri G; Gholami K; Salamzadeh J; Maghooli G; Mirsaeedi SM
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1104-10. PubMed ID: 17823987
[TBL] [Abstract][Full Text] [Related]
7. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
[TBL] [Abstract][Full Text] [Related]
8. Bracelet- and self-directed observational therapy for control of tuberculosis: study protocol for a cluster randomized controlled trial.
Huang R; Ren G; Hu J
Trials; 2017 Jul; 18(1):286. PubMed ID: 28673323
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial.
Nyang'wa BT; Kloprogge F; Moore DAJ; Bustinduy A; Motta I; Berry C; Davies GR
BMJ Open; 2021 Sep; 11(9):e047185. PubMed ID: 34489274
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of adverse reactions induced by anti-tuberculosis drugs among hospitalized patients in Wuhan, China: A retrospective study.
Shi C; Yang B; Yang J; Song W; Chen Y; Zhang S; Zhan H; Xiong Y; Rong P; Luo Y; Yang J
Medicine (Baltimore); 2024 May; 103(20):e38273. PubMed ID: 38758847
[TBL] [Abstract][Full Text] [Related]
11. Incidence and outcomes of adverse drug reactions to first-line anti-tuberculosis drugs and their effects on the quality of life: A multicenter prospective cohort study.
Choi H; Park HA; Hyun IG; Kim JH; Hwang YI; Jang SH; Sim YS; Shin TR; Ko Y; Ban GY; Hong JY; Lee CY; Lee MG; Choi JH
Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1153-1163. PubMed ID: 35909258
[TBL] [Abstract][Full Text] [Related]
12. Cohort Study of Pulmonary Tuberculosis (COSMOTB) identifying drug-resistant mutations: protocol for a prospective observational study in Korea.
Min J; Chung C; Lim J; Park JH; Shin KS; Jung SS; Lee KM
BMJ Open; 2018 Oct; 8(10):e021235. PubMed ID: 30309990
[TBL] [Abstract][Full Text] [Related]
13. Assessing the prevalence and effect of adverse drug reactions among patients receiving first line anti-tubercular medicines in the Tamale Teaching Hospital, Ghana.
Amalba A; Bugri AA
Pan Afr Med J; 2021; 38():191. PubMed ID: 33995797
[TBL] [Abstract][Full Text] [Related]
14. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
16. Impact of the change in the antitubercular regimen from three to four drugs on cure and frequency of adverse reactions in tuberculosis patients from Brazil: A retrospective cohort study.
Arriaga MB; Torres NMC; Araujo NCN; Caldas SCC; Andrade BB; Netto EM
PLoS One; 2019; 14(12):e0227101. PubMed ID: 31877199
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of acupressure to prevent adverse reactions to anti-tuberculosis drugs: Randomized controlled trials.
Hsieh CJ; Su WJ; Wu SC; Chiu JH; Lin LC
J Adv Nurs; 2019 Mar; 75(3):640-651. PubMed ID: 30375013
[TBL] [Abstract][Full Text] [Related]
18. Correlation between lncRNA AC079767.4 variants and liver injury from antituberculosis treatment in West China.
Zhao Z; Peng W; Wu L; Ying B
J Infect Chemother; 2020 Jan; 26(1):63-68. PubMed ID: 31405785
[TBL] [Abstract][Full Text] [Related]
19. Adverse Drug Reaction Patterns of First-line Anti-tubercular Drugs among Saharia Tuberculosis Patients: An Observational Study in Particularly Vulnerable Tribal Group of Madhya Pradesh, India.
Mishra P; Bhat J; Yadav R; Sharma RK; Rao VG
Indian J Public Health; 2023 Oct; 67(4):542-545. PubMed ID: 38934815
[TBL] [Abstract][Full Text] [Related]
20. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
